{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:33:23Z","timestamp":1783114403290,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001064","name":"Epilepsy Society of Australia Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.yebeh.2025.110441","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:11:46Z","timestamp":1745687506000},"page":"110441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The outcome of ceasing valproate before pregnancy in women with epilepsy"],"prefix":"10.1016","volume":"169","author":[{"given":"Frank","family":"Vajda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8307","key":"10.1016\/j.yebeh.2025.110441_b0005","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(82)90018-6","article-title":"Valproic acid and spina bifida","volume":"2","author":"Bjerkedal","year":"1982","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110441_b0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/000992288302200502","article-title":"Valproic acid in pregnancy-association with spina bifida: a preliminary report","volume":"22","author":"Robert","year":"1983","journal-title":"Clin Pediatr (Phila)"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110441_b0015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic drugs and pregnancy outcomes","volume":"158A","author":"Wlodarczyk","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110441_b0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/jnnp-2013-306318","article-title":"Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers","volume":"85","author":"Campbell","year":"2014","journal-title":"JNeurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110441_b0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200822040-00004","article-title":"Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect","volume":"22","author":"Diav-Citrin","year":"2008","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110441_b0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110441_b0035","doi-asserted-by":"crossref","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F; EURAP Study Group.. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 2015 Sep 8;85(10):866\u201372. 10.1212\/WNL.0000000000001772 24.","DOI":"10.1212\/WNL.0000000000001840"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110441_b0040","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"EURAP Study Group.. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"16","key":"10.1016\/j.yebeh.2025.110441_b0045","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2025.110441_b0050","doi-asserted-by":"crossref","unstructured":"Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, Tudur Smith C, Marson AG. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014 Oct 30;2014(10):CD010236. doi: 10.1002\/14651858.CD010236.pub2. PMID: 25354543.","DOI":"10.1002\/14651858.CD010236.pub2"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110441_b0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","article-title":"Liverpool and Manchester Neurodevelopment Group. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study","volume":"84","author":"Baker","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110441_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017248","article-title":"Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis","volume":"7","author":"Veroniki","year":"2017","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110441_b0065","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110441_b0070","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209175","article-title":"Neurodevelopmental and Functional Outcomes Following In Utero Exposure to Antiseizure Medication: A Systematic Review","volume":"102","author":"Honybun","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110441_b0075","doi-asserted-by":"crossref","unstructured":"Andrade C. Valproate in Pregnancy: Recent Research and Regulatory Responses. J Clin Psychiatry. 2018 May\/Jun;79(3):18f12351. doi: 10.4088\/JCP.18f12351. PMID: 29873961.","DOI":"10.4088\/JCP.18f12351"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2025.110441_b0080","first-page":"1","article-title":"Why do some women with epilepsy use valproic acid despite current guidelines?","volume":"98","author":"Bosak","year":"2019","journal-title":"A single-center cohort study Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110441_b0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2020.03.015","article-title":"The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre","volume":"79","author":"Davies","year":"2020","journal-title":"Seizure"},{"issue":"10024","key":"10.1016\/j.yebeh.2025.110441_b0090","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0140-6736(16)30013-7","article-title":"France steps up warning measures for valproate drugs","volume":"387","author":"Casassus","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110441_b0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110441_b0100","unstructured":"European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. 23 March 2018. Link: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf (accessed: 7 January 2025)."},{"key":"10.1016\/j.yebeh.2025.110441_b0105","unstructured":"Medicines and Healthcare products Regulatory Agency. New valproate safety measures apply from 31 January. 31 January 2024. Link: https:\/\/www.gov.uk\/government\/news\/new-valproate-safety-measures-apply-from-31-january (accessed: 7 January 2025)."},{"issue":"10","key":"10.1016\/j.yebeh.2025.110441_b0110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00415-002-0857-3","article-title":"Non convulsive status epilepticus after replacement of valproate with lamotrigine","volume":"249","author":"Trinka","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110441_b0115","doi-asserted-by":"crossref","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F; EURAP Study Group. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. Epilepsia. 2016 Aug;57(8):e173-7. doi: 10.1111\/epi.13437. PMID: 27319360.","DOI":"10.1111\/epi.13437"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110441_b0120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ane.13005","article-title":"Valproate-associated foetal malformations-Rates of occurrence, risks in attempted avoidance","volume":"139","author":"Vajda","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110441_b0125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jocn.2006.08.015","article-title":"The Australian antiepileptic drug in pregnancy register: aspects of data collection and analysis","volume":"14","author":"Vajda","year":"2007","journal-title":"J Clin Neurosci"},{"issue":"12","key":"10.1016\/j.yebeh.2025.110441_b0130","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jocn.2010.05.008","article-title":"The Australian Pregnancy Register of Anti-epileptic Drugs: 10 years of progress","volume":"17","author":"Vajda","year":"2010","journal-title":"J Clin Neurosci"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110441_b0135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jocn.2013.11.049","article-title":"The Australian Register of antiepileptic drugs in pregnancy: changes over time in the epileptic population","volume":"21","author":"Vajda","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110441_b0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1440-1754.1998.00208.x","article-title":"Congenital malformations in Victoria, Australia, 1983-95: an overview of infant characteristics","volume":"34","author":"Riley","year":"1998","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110441_b0145","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/epi.16505","article-title":"Pregnancy after valproate withdrawal-Fetal malformations and seizure control","volume":"61","author":"Vajda","year":"2020","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110441_b0150","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1528-1167.2007.01412.x","article-title":"Seizure control in antiepileptic drug-treated pregnancy","volume":"49","author":"Vajda","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110441_b0155","doi-asserted-by":"crossref","unstructured":"Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Allen Hauser W, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009 May;50(5):1229-36. doi: 10.1111\/j.1528-1167.2009.02128.x. PMID: 19496807.","DOI":"10.1111\/j.1528-1167.2009.02128.x"},{"key":"10.1016\/j.yebeh.2025.110441_b0160","doi-asserted-by":"crossref","unstructured":"Thomas SV, Syam U, Devi JS. Predictors of seizures during pregnancy in women with epilepsy. Epilepsia. 2012 May;53(5):e85-8. doi: 10.1111\/j.1528-1167.2012.03439.x. PMID: 22429269.","DOI":"10.1111\/j.1528-1167.2012.03439.x"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:54:44Z","timestamp":1766152484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S1525505025001805"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110441","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The outcome of ceasing valproate before pregnancy in women with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110441"}}